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S 4 ( 2 0 0 6 ) 2 7 –5 3Background: Previously we showed that oncogene Ha-Ras stim-ulates the metastatic activity of both spontaneously transformed
and v-src-transformed Syrian hamster fibroblasts in vivo. We
revealed that Ha-Ras/RalGDS/Ral-associated signalling pathway
was the most important for metastasis among the variety of
Ha-Ras associated signaling cascades.
Methods: Retroviral infection, molecular cloning, spontaneous
metastatic activity, gelatine zymography, RT-PCR, cell viability
assay, peroxide decomposition activity assay.
Results: We showed that both RalA and RalB stimulate the meta-
static potential of cells, but RalB is less efficient than RalA. To
understand what Ral interacting proteins contribute to this phe-
nomenon we compared the level of metastatic potential of the cell
lines expressing RalA and RalB effecter domain mutants. The
search revealed that among the three best-studied Ral downstream
partners RalA-PLD1 and RalB-RalBP1/RalB-Sec5 interactions were
essential. The introduction of active form of RalA (RalA+ cells),
unlike RalB, downregulates the secretion of MMP1, MMP2 and
MMP9 in comparison to parental cells, although the cocultivation
of RalA+ cells with hamster embryo fibroblasts leaded to stimula-
tion of MMPs secretion suggesting that RalA+ cells can it in stromal
cells. The highly metastatic cells acquired the peroxide resistance
as well as peroxide decomposition activity and this viability may
serve as a protection against the host immune system.
Conclusion: RalB can stimulate metastatic ability of transformed
cells, but less than RalA. These two closely-related proteins prob-
ably stimulate metastasis through distinct downstream signaling
pathways. MMPs secretion is involved in Ral-dependent metasta-
sis, but RalA and RalB utilize different cellular mechanisms.
doi:10.1016/j.ejcsup.2006.04.073
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Background: The ADAMs are a family of transmembrane, multi-
domain proteins, involved in both cellular adhesion and proteol-
ysis. Multiple studies from model systems suggest that specific
ADAMs are involved in cancer progression. The aim of this inves-
tigation was to see if ADAM-17 was involved in the progression of
human breast cancer.
Materials, Methods and Results: ADAM-17 protein was mea-
sured by both Western blotting and ELISA. ADAM-17 protein
was found to exist in two main forms in human breast tissue, a
120 kDa precursor and 100 kDa active protein. Both forms of
ADAM-17 protein were found to be upregulated in primary breast
carcinomas compared to normal breast tissue (Mann–Whitney U-
test: p = 0.005, p = 0.0003, respectively). The ratio of 100 kDa pro-
tein to 120 kDa protein increased with disease progression from
normal breast tissue to axillary node metastases (Kruskal–Wallis
statistical test: p = 0.002), indicating an increase in processing
from precursor to active protein in malignant breast tissue.
32 E J C S U P P L E M E N TA moderate, but significant correlation was found between the
100 kDa form of ADAM-17 (measured by Western blotting) and
ADAM-17 levels determined by ELISA (Spearman Rank:
p = 0.0006, r = 0.405). No significant relationship was found
between the 120 kDa protein form and levels measured by ELISA.
ADAM-17 protein levels, as measured by ELISA, were significantly
higher in grade 3 tumours as compared to tumours classed as
grades 1 and 2 (Mann–Whitney U-test: p = 0.03), and in node-posi-
tive compared to node-negative cancers (Mann–Whitney U-test:
p = 0.04). Furthermore, both forms of ADAM-17 correlated with
cell proliferation, as measured by PCNA (Spearman Rank:
r = 0.524, p < 0.0001; r = 0.365, p = 0.002, respectively) and with
metastatic potential, as measured by uPA (Spearman Rank:
r = 0.246, p = 0.032; r = 0.428, p = 0.0001, respectively).
Conclusion: We conclude that ADAM-17 protein exists in two
main forms in breast cancer. Furthermore, our results suggest
that ADAM-17 is involved in breast cancer progression.
doi:10.1016/j.ejcsup.2006.04.074
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Background: Pancreatic cancer is the fifth most frequent cause of
cancer-related deaths in industrialized countries. The diagnosis of
ductal adenocarcinoma of the pancreas is associated with a poor
prognosis, an increasing incidence and no or only ineffective
means of treatment. Cystic pancreatic neoplasms account only
approximately 5% of primary malignancies of the pancreas and
may be benign, pre-malignant or malignant. In this study, we are
developing and evaluating a DNA-diagnostic-chip with about 3500
human genes known to be differentially transcribed in pancreatic
cancer cells and thus expected to show a representative expression
pattern in both ductal adenocarcinoma and cystic lesions.
Methods: cDNAs representing different human genes were PCR-
amplified, purified and robotically arrayed onto slides with an
epoxy surface. Fluorescently labelled cDNA samples were pre-
pared from total RNA isolated from cells of human pancreas tissue
by incorporation of labelled dCTPs during reverse transcription.
Results: Microarray experiments on various samples are being
performed and analysed allowing classification of different types
of pancreas lesions and the identification of potential targets as a
means of eventually developing new modes of treatment.
Conclusion: The resulting diagnostic DNA-chip will be of signif-
icant clinical utility to detect cancer cells in tissues from patients
with different types of pancreatic carcinoma and to draw prog-
nostic conclusions based on their molecular appearance. Further-
more, comparative studies on transcriptional profiling and actual
protein expression by means of complex DNA- and antibody
microarrays are under way.
doi:10.1016/j.ejcsup.2006.04.075
